Chinese specialty pharmaceutical firm Eddingpharm has received an exclusive, royalty-bearing license from Ablynx to develop and commercialize its anti-RANKL Nanobody, ALX-0141, in China, the Hong Kong and Macao Special Administrative ...
Tags: Eddingpharm, Anti-Rankl Nanobody